

**ASX ANNOUNCEMENT**

21 DECEMBER 2018

RESPIRI LIMITED | SHARE PURCHASE PLAN**Share Purchase Plan Indicative Timetable**

Further to the ASX announcement by Respiri Limited (ASX: RSH) (the **Company**) of 18 December 2018, the Company is pleased to provide shareholders with the following indicative timetable for the Company's upcoming Share Purchase Plan (**SPP**):

Event	Date
Record Date	7.00pm (AEDT), Monday, 17 December 2018
Distribution of SPP booklet (containing terms and conditions of the SPP)	Monday, 7 January 2019
SPP offer opens	10.00am (AEDT time), Thursday, 10 January 2019
SPP offer closes	5.00pm (AEDT time), Thursday, 31 January 2019
SPP results announcement	Monday, 4 February 2019
Issue and allotment of New Securities	Monday, 11 February 2019
Dispatch of holding statements	Tuesday, 12 February 2019
Expected quotation of and trading date of new Shares on ASX	Tuesday, 12 February 2019

The timetable above is indicative only and remains subject to change. Respiri reserves the right to alter the above dates at its sole discretion and without notice, subject to the ASX Listing Rules and the *Corporations Act 2001* (Cth). The commencement of trading of any new RSH fully paid ordinary shares is subject to confirmation from ASX.

Further information in relation to the terms of the SPP will be released in the SPP booklet on or about the date provided for in the table above. Respiri confirms that the pricing of the SPP will be at \$0.08 per share, which is consistent with the terms offered to institutional and sophisticated investors under the Placement, completion of which was announced to ASX on 18 December 2018.

Mario Gattino
CEO

---END---

ABOUT RESPIRI LIMITED

Respiri's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

FORWARD LOOKING STATEMENTS

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.